Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents

摘要

A series of new pyrazolines containing 2,5 -dichloro-3-acetylthiophene cha lcone moiety (PZT1-PZT20) have been synthesized, characterized by 1HNMR and 13CNMR and evaluated for them in vitro antitubercular activity against M. tuberculosis H37Rv strain and in vitro anticancer activity against DU-145 prostate cancer cell lines. Majority of screened compounds have displayed potential activity against Mycobacterium tuberculosis H37Rv (MTB) strain and anticancer activity against DU149 prostate cancer cell lines. Among the series, compound PZT5 with 2”, 4”-dichlorophenyl group at 5-position on the pyrazoline ring exhibited the most potent antitubercular activity (MIC=1.60 μg/mL) and compounds PZT2, PZT9, PZT11, PZT15, and PZT20 showed similar antitubercular activity against standard pyrazinamide (MIC=3.12 μg/mL) by broth dilution assay. PZT15 and PZT17 with 4”-pyridinyl and 2”-pyrrolyl groups on pyrazoline ring were found to exhibit better anticancer activity against DU-149 prostate cancer cell lines with IC50 values of 2.0±0.2 μg/mL and 6.0±0.3 μg/mL respectively by MTT assay. The preliminary structure-activity relationship has been summarized. The molecular docking studies with crystalline structures of enoyl acyl carrier protein reductase InhA interaction with target protein (2NSD; PDB and 3FNG; PDB) of Mycobacterium tuberculosis H37Rv (MTB) strain have also exhibited good ligand interaction and binding affinity. Ligand interaction and binding affinity were estimated using crystal structures of both types of enoyl acyl carrier protein reductase InhA (3FNG.pdb) and found to be much higher (-16.70 to -19.20 kcal/mol) compared with pyrazinamide (-10.70 kcal/mol) as a standard target molecule. Whereas the binding affinities of six active compounds with crystal structure of other type of enoyl acyl carrier protein reductase InhA (2NSD.pdb) were much similar and higher (-9.30 to -11.20 kcal/mole) than pyrazinamide (-11.10 kcal/mole). These new pyrazolines would be promising potent inhibitors of drug sensitive and drugresistant Mycobacterium tuberculosis strain and potential anticancer agents against prostate cancer and other prototypes of cancers.